Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene

NCT04517149 is registered in ClinicalTrials.gov with 4D Molecular Therapeutics as lead sponsor.

NCT NCT04517149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04517149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
Lead sponsor
4D Molecular Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 9, 2020
Completion date
May 31, 2029
Enrollment
21 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked retinitis pigmentosa